Core medicines drive UCB sales up 7% – PharmaTimes

by admin on February 27, 2013

Core medicines drive UCB sales up 7%
PharmaTimes
for rheumatoid arthritis and Crohn's disease up 50% at 467 million euros; the antiepileptic Vimpat (lacosamide) up 53% at 334 million euros, and Neupro (rotigotine), a patch for Parkinson's disease and restless legs syndrome, up 40% to 133 million
UCB : in 2012: New Core Medicines Drive Growth4-traders (press release)

all 3 news articles »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: